Sanjay Chanda insider trades

Open-market stock purchases and sales by Sanjay Chanda, Chief Development Officer at AN2 Therapeutics, Inc, from SEC Form 4 filings since Apr 12, 2013.

Recent trades

DateStockTradeValue
Mar 19, 2026ANTX AN2 Therapeutics, IncBought (not open market)$258K
Mar 19, 2026ANTX AN2 Therapeutics, IncSold (not open market)$1.1M
Mar 19, 2026ANTX AN2 Therapeutics, IncBought (not open market)$227K
Mar 19, 2026ANTX AN2 Therapeutics, IncSold (not open market)$828K
Mar 19, 2026ANTX AN2 Therapeutics, IncBought (not open market)$163K
Mar 19, 2026ANTX AN2 Therapeutics, IncSold (not open market)$275K
Feb 20, 2026ANTX AN2 Therapeutics, IncBought (not open market)—
Feb 20, 2026ANTX AN2 Therapeutics, IncBought (not open market)—
Jan 6, 2026ANTX AN2 Therapeutics, IncSold$6K
Jan 5, 2026ANTX AN2 Therapeutics, IncSold$3.3K

Companies traded

  • ANTX AN2 Therapeutics, Inc: 3 sales, last Mar 19, 2026
  • ANAC Anacor Pharmaceuticals, Inc: 5 sales, last Mar 4, 2015

Get free alerts when Sanjay Chanda files a new trade →